Drug intelligence / Profile preview

T1675

Development stage: Phase 2
Lead developer: Théa Pharmaceuticals
Administration: Oral

Overview

T1675 is an orally administered dietary formulation of omega-3 and omega-6 polyunsaturated essential fatty acids developed by Théa for moderate dry eye syndrome in patients already using tear substitutes. It was evaluated against placebo during six months of supplementation in a registered clinical study; the publicly available trial description does not identify the individual fatty acids, their doses, or a specific molecular target. ([clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00357201))

Beyond the preview

Go deeper on T1675.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on T1675.

Explore the full profile